Publication:
Activated Clotting Time and Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights from the PROGRESS-CTO Registry

dc.authorscopusid57196825800
dc.authorscopusid57861089600
dc.authorscopusid57357868900
dc.authorscopusid58417166300
dc.authorscopusid56209450200
dc.authorscopusid6505946630
dc.authorscopusid57511019600
dc.contributor.authorSimsek, B.
dc.contributor.authorRempakos, A.
dc.contributor.authorKostantinis, S.
dc.contributor.authorAlexandrou, M.
dc.contributor.authorGörgülü, S.
dc.contributor.authorAlaswad, K.
dc.contributor.authorFrizzell, J.D.
dc.date.accessioned2025-12-11T00:32:03Z
dc.date.issued2023
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Simsek] Bahadir, Minneapolis Heart Institute, Minneapolis, MN, United States; [Rempakos] Athanasios, Minneapolis Heart Institute, Minneapolis, MN, United States; [Kostantinis] Spyridon T., Minneapolis Heart Institute, Minneapolis, MN, United States; [Alexandrou] Michaella, Minneapolis Heart Institute, Minneapolis, MN, United States; [Görgülü] Şevket, Department of Cardiology, Biruni Üniversitesi, Istanbul, Turkey; [Alaswad] Khaldoon, Division of Cardiology, Henry Ford Hospital, Detroit, MI, United States; [Frizzell] Jarrod D., Department of Cardiology, The Christ Hospital - Cincinnati, Cincinnati, OH, United States; [Yildirim] Ufuk, Department of Cardiology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Poommipanit] Paul B., University Hospitals Case Medical Center, Cleveland, OH, United States; [Aygül] Nazif, Department of Cardiology, Selçuk Üniversitesi, Selçuklu, Konya, Turkey; [Abi-Rafeh] Nidal, North Oaks Healthcare System, Hammond, LA, United States; [Bagur] Rodrigo H., Department of Cardiology, Western University, London, ON, Canada; [Davies] Rhian E., Department of Cardiology, York Hospital, Pennsylvania, York, PA, United States; [Göktekín] Ömer, Memorial Bahcelievler Hospital, Istanbul, Istanbul, Turkey; [Choi] James W., Department of Cardiology, Presbyterian Hospital of Dallas, Dallas, TX, United States; [Reddy] Niranjan, Department of Cardiology, Kettering Health Network, Dayton, OH, United States; [Dattilo] Phil B., UCHealth Medical Center of the Rockies, Loveland, CO, United States; [Kerrigan] Jimmy Lee, Saint Thomas Heart Hospital, Nashville, TN, United States; [Haddad] Elias Victor, Saint Thomas Heart Hospital, Nashville, TN, United States; [Mastrodemos] Olga C., Minneapolis Heart Institute, Minneapolis, MN, United States; [Rangan] Bavana V., Minneapolis Heart Institute, Minneapolis, MN, United States; [Karácsonyi] Judit, Minneapolis Heart Institute, Minneapolis, MN, United States; [Allana] Salman Saleem, Minneapolis Heart Institute, Minneapolis, MN, United States; [Kearney] Kathleen E., University of Washington School of Medicine, Seattle, WA, United States; [Sandoval] Yader B., Minneapolis Heart Institute, Minneapolis, MN, United States; [Burke] Martin Nicholas, Minneapolis Heart Institute, Minneapolis, MN, United States; [Brilakis] Emmanouil S., Minneapolis Heart Institute, Minneapolis, MN, United States; [Azzalini] Lorenzo, University of Washington School of Medicine, Seattle, WA, United Statesen_US
dc.description.abstractBackground. The optimal range of activated clotting time (ACT) in chronic total occlusion (CTO) percutaneous coronary intervention (PCI) has received limited study. Methods. We examined the association between ACT and in-hospital ischemic and bleeding outcomes in patients who underwent CTO PCI in the Prospective Global Registry for the Study of CTO Intervention. Results. ACT values were available for 4377 patients who underwent CTO PCI between 2012 and 2023 at 29 centers. The mean ACT distribution was less than 250 seconds (19%), 250 to 349 seconds (50%), and greater than or equal to 350 seconds (31%). The incidence of ischemic events, bleeding events, and net adverse cardiovascular events (NACE) was 0.8%, 3.0%, and 3.8%, respectively. In multiple logistic regression analysis, increasing nadir ACT was associated with decreasing ischemic events (adjusted odds ratio [aOR] per 50-second increments: 0.69 [95% confidence interval (CI), 0.50-0.94; P= .017]; and increasing peak ACT was associated with increasing bleeding events (aOR per 50-second increments: 1.17 [95% CI,1.01-1.36; P= .032]). A U-shaped association was seen between mean ACT and NACE, where restricted cubic spline analysis demonstrated that patients with a low (<200 seconds) or high (>400 seconds) ACT had increasing NACE risk compared with an ACT of 200 to 400 seconds (aOR 2.06, 95% CI 1.18-3.62; P= .012). Conclusions. Among patients who underwent CTO PCI, mean ACT had a U-shaped relationship with NACE, where patients with a low (<200 seconds) ACT (driven by ischemic events) or high (>400 seconds) ACT (driven by bleeding) had higher NACE compared with an ACT of 200 to 400 seconds. © 2023 HMP Global. All Rights Reserved.en_US
dc.identifier.doi10.25270/jic/23.00170
dc.identifier.issn1042-3931
dc.identifier.issn1557-2501
dc.identifier.issue12en_US
dc.identifier.scopus2-s2.0-85201691145
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.25270/jic/23.00170
dc.identifier.urihttps://hdl.handle.net/20.500.12712/37117
dc.identifier.volume35en_US
dc.identifier.wosqualityQ3
dc.language.isoenen_US
dc.publisherCliggott Publishing Co.en_US
dc.relation.ispartofJournal of Invasive Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectActivateden_US
dc.subjectBleedingen_US
dc.subjectCardiovascularen_US
dc.subjectChronic Totalen_US
dc.subjectClotting Timeen_US
dc.subjectCoronaryen_US
dc.subjectEventsen_US
dc.subjectInterventionen_US
dc.subjectIschemiaen_US
dc.subjectNet Adverseen_US
dc.subjectOcclusionen_US
dc.subjectPercutaneousen_US
dc.titleActivated Clotting Time and Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights from the PROGRESS-CTO Registryen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files